Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$232.64
+0.9%
$214.84
$163.81
$244.81
$410.95B0.516.48 million shs1.73 million shs
Amgen Inc. stock logo
AMGN
Amgen
$293.77
+1.3%
$286.77
$253.30
$335.88
$158.21B0.492.77 million shs481,377 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%-1.36%+5.71%+20.54%+18.89%
Amgen Inc. stock logo
AMGN
Amgen
0.00%-2.60%+4.97%-2.32%-11.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$232.64
+0.9%
$214.84
$163.81
$244.81
$410.95B0.516.48 million shs1.73 million shs
Amgen Inc. stock logo
AMGN
Amgen
$293.77
+1.3%
$286.77
$253.30
$335.88
$158.21B0.492.77 million shs481,377 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%-1.36%+5.71%+20.54%+18.89%
Amgen Inc. stock logo
AMGN
Amgen
0.00%-2.60%+4.97%-2.32%-11.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.79
Moderate Buy$231.90-0.32% Downside
Amgen Inc. stock logo
AMGN
Amgen
2.35
Hold$309.425.33% Upside

Current Analyst Ratings Breakdown

Latest ABBV and AMGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/13/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
10/10/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$231.00 ➝ $284.00
10/9/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetOverweight$250.00
10/8/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
10/8/2025
Amgen Inc. stock logo
AMGN
Amgen
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+)Buy (B-)
10/3/2025
AbbVie Inc. stock logo
ABBV
AbbVie
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$251.00
10/3/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$220.00 ➝ $251.00
10/2/2025
AbbVie Inc. stock logo
ABBV
AbbVie
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$225.00
10/1/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
10/1/2025
AbbVie Inc. stock logo
ABBV
AbbVie
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold
9/27/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$56.33B7.30$15.07 per share15.44$1.90 per share122.44
Amgen Inc. stock logo
AMGN
Amgen
$33.42B4.73$30.76 per share9.55$10.93 per share26.88
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.28B$2.10110.7716.641.426.45%699.66%13.64%10/31/2025 (Estimated)
Amgen Inc. stock logo
AMGN
Amgen
$4.09B$12.2324.0313.732.5218.96%174.71%13.12%11/4/2025 (Estimated)

Latest ABBV and AMGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2025Q3 2025
Amgen Inc. stock logo
AMGN
Amgen
$5.01N/AN/AN/A$8.98 billionN/A
10/31/2025Q3 2025
AbbVie Inc. stock logo
ABBV
AbbVie
$3.26N/AN/AN/A$15.58 billionN/A
8/5/2025Q2 2025
Amgen Inc. stock logo
AMGN
Amgen
$5.28$6.02+$0.74$2.65$8.86 billion$9.18 billion
7/31/2025Q2 2025
AbbVie Inc. stock logo
ABBV
AbbVie
$3.24$2.97-$0.27$0.52$14.93 billion$15.42 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.562.82%N/A312.38%53 Years
Amgen Inc. stock logo
AMGN
Amgen
$9.523.24%N/A77.84%14 Years

Latest ABBV and AMGN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/5/2025
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.643.08%10/15/202510/15/202511/14/2025
8/1/2025
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.383.21%8/22/20258/22/20259/12/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
44.14
0.74
0.61
Amgen Inc. stock logo
AMGN
Amgen
7.24
1.31
0.98

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Amgen Inc. stock logo
AMGN
Amgen
76.50%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.08%
Amgen Inc. stock logo
AMGN
Amgen
0.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
55,0001.77 billion1.77 billionOptionable
Amgen Inc. stock logo
AMGN
Amgen
28,000538.36 million534.65 millionOptionable

Recent News About These Companies

Cantor Fitzgerald Has Negative View of Amgen FY2025 Earnings
FY2025 Earnings Estimate for Amgen Issued By William Blair
Keener Financial Planning LLC Raises Stake in Amgen Inc. $AMGN
Amgen Inc. $AMGN Shares Acquired by Cwm LLC
Sather Financial Group Inc Grows Stake in Amgen Inc. $AMGN
RBC Capital Reaffirms Their Buy Rating on Amgen (AMGN)
Amgen (AMGN) Receives a Hold from Raymond James
FY2026 EPS Estimates for Amgen Lifted by Cantor Fitzgerald
Here's What to Expect From Amgen’s Next Earnings Report

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$232.64 +2.14 (+0.93%)
As of 12:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Amgen stock logo

Amgen NASDAQ:AMGN

$293.77 +3.64 (+1.25%)
As of 12:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.